GM-CSF With Post-Transplant Cyclophosphamide

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

Inclusion Criteria:

• Availability of 5/10 to 8/10 matched related donor
• KPS >/= 70%
• CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center

Exclusion Criteria:

• Poor cardiac, pulmonary, liver, and renal function
• HIV-positive
• Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent
• History of severe or serious allergic reaction to human GM-CSF or yeast-derived products